Taken altogether, these results suggest that the EBF3 promoter hypermethylation and gene body hypomethylation is associated with tumour progression and metastasis, and it might be a characteristic aggressive change shared by both melanoma and colorectal cancer. This evidence concerns the gene EBF3 and colorectal cancer.